A Phase 1 interventional study of HSK3486 in Anesthesia and Sedation, sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd. Withdrawn. Open to male participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-02.
Sponsored by Sichuan Haisco Pharmaceutical Group Co., Ltd (part of Haisco Pharmaceutical Group Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is designed to evaluate the mass balance in healthy Chinese male subjects after receiving a single dose of intravenous [14C]HSK3486, so as to assess the overall pharmacokinetics and safety of HSK3486 in humans and provide a reference for reasonable use of this drug.
Sichuan Haisco Pharmaceutical Group Co., Ltd is the lead sponsor of 30 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects enrolled in this study are required to meet all of the following:
Exclusion Criteria:
Subjects who meet any of the following will be excluded:
Past and current medical history:
A Subjects with a history of any severe disease, or concomitant diseases or abnormalities that may affect the test results as judged by the investigator, including but not limited to diseases or abnormalities in the circulatory system, endocrine system, neurological system, digestive system, urinary system, hematologic system, immune system, mental and metabolic aspects; B Subjects who have a past or current history of cardiovascular disease, including: heart failure, ischemic heart disease, long syndrome, arrhythmia requiring medication; a family history of Adams-Stokes syndrome or long QT syndrome; QTcF interval ≥ 450 ms (corrected by Fridericia's formula); C Subjects who have a past or current history of respiratory disease, including: obstructive pulmonary disease, asthma, or a history of bronchospasm requiring treatment within 3 months prior to screening; acute respiratory infections within 1 week prior to screening, with significant fever, wheezing, nasal congestion, and coughing.
D Subjects who have a past or current history of gastrointestinal disease, including: gastroesophageal reflux, hemorrhoids or perianal disease with fecal blood, habitual constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease, etc.; E Subjects who have major surgery within 6 months before screening, or surgical incision not completely healed. Major surgery includes, but is not limited to any surgery that has a significant risk of bleeding, prolonged general anesthesia, incisional or significant traumatic injury; F Subjects with hyperactive immune response, including: sensitive to of HSK3486 emulsion injections (soybean oil, glycerin, triglyceride, egg lecithin, sodium oleate and sodium hydroxide), history of drug allergies (including anesthetics), or other allergic diseases (such as allergic to any food ingredient or have special dietary requirements and cannot follow a uniform diet);
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.4 mg/kg of HSK3486 emulsion injection (containing \[14C\] HSK3486 at a radiation dose of 5 nCi/0.4 mg/kg) .
Drug: HSK3486
The first 2 subjects will receive an intravenous injection of 0.4 mg/kg of HSK3486 emulsion injection (containing \[14C\] HSK3486 at a radiation dose of 5 nCi/0.4 mg/kg, i.e. a subject with the body weight of 60 kg is administered with a radiation dose of 300 nCi). The radiation dose for subsequent subjects can be adjusted based on the results of the first 2 subjects.
Percentage of cumulative drug excretion of [14C]HSK3486 on biological specimens(urine and faeces) accounting for total radiation drug dose
Though collecting different periods of biological specimens(urine and faeces) , detecting their respective drug excretion of \[14C\]HSK3486,calculating the total cumulative excretion amount and relevant proportion of each kind of specimen(urine or faeces).
Time frame: from the start of administration to 96 hours after administration
Maximum Plasma Concentration [Cmax] of 14C radioactivity and non-radiolabeled HSK3486 respectively
Pharmacokinetic Measures
Time frame: from the start of administration to 96 hours after administration
Time to plasma peak concentration[Tmax] of 14C radioactivity and non-radiolabeled HSK3486 respectively
Pharmacokinetic Measures
Time frame: from the start of administration to 96 hours after administration
Clearance half-life[t1/2] of 14C radioactivity and non-radiolabeled HSK3486 respectively
Pharmacokinetic Measures
Time frame: from the start of administration to 96 hours after administration
Area Under the Curve [AUC] of 14C radioactivity and non-radiolabeled HSK3486 respectively
Pharmacokinetic Measures
Time frame: from the start of administration to 96 hours after administration
Number of patients with adverse events and serious adverse events
Safety Measures
Time frame: From the time the subject is being screened to the end of the trial( nearly 96h after drug administration)
Blood routine test
Observe the changes of blood routine test during the whole trial
Time frame: At the time of subject is being screened and at the end of study( nearly 96h after drug administration)
Urine routine test
Observe the changes of urine routine test during the whole trial
Time frame: At the time of subject is being screened and at the end of study( nearly 96h after drug administration)
Blood biochemical examination
Observe the changes of Blood biochemical examination during the whole trial
Time frame: At the time of subject is being screened and at the end of study( nearly 96h after drug administration)
Blood pressure
Observe the changes of blood pressure during the whole trial
Time frame: From the time the subject is being screened to the end of the trial( nearly 96h after drug administration)
Heart rate or pulse
Observe the changes of heart rate or pulse during the whole trial
Time frame: From the time the subject is being screened to the end of the trial( nearly 96h after drug administration)
Respiratory rate or blood oxygen saturation
Observe the changes of respiratory rate or blood oxygen saturation during the whole trial
Time frame: From the time the subject is being screened to the end of the trial( nearly 96h after drug administration)
Heart rate of electrocardiogram
Observe the changes of heart rate of electrocardiogram during the whole trial
Time frame: From the time the subject is being screened to the end of the trial( nearly 96h after drug administration)
RR interval of electrocardiogram
Observe the changes of RR interval of electrocardiogram during the whole trial
Time frame: From the time the subject is being screened to the end of the trial( nearly 96h after drug administration)
QT interval of electrocardiogram
Observe the changes of QT interval of electrocardiogram during the whole trial
Time frame: From the time the subject is being screened to the end of the trial( nearly 96h after drug administration)
QTcF interval of electrocardiogram
Observe the changes of QTcF interval of electrocardiogram during the whole trial
Time frame: From the time the subject is being screened to the end of the trial( nearly 96h after drug administration)
PR interval of electrocardiogram
Observe the changes of PR interval of electrocardiogram during the whole trial
Time frame: From the time the subject is being screened to the end of the trial( nearly 96h after drug administration)
QRS interval of electrocardiogram
Observe the changes of QRS interval of electrocardiogram during the whole trial
Time frame: From the time the subject is being screened to the end of the trial( nearly 96h after drug administration)
No study locations are listed for this record.
Ran from Mar 2020 to primary completion in Nov 2020, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ciprofol
Sichuan Haisco Pharmaceutical Group Co., Ltd →